I **couldnâ€™t find credible, detailed scientific or clinical pharmacological data on something called â€œpeptide complex A-7â€ as a defined pharmacological agent** in the published literature or regulatory sources. There **is no recognized therapeutic peptide with that exact name in established research or drug databases**; no published values for human pharmacological actions, half-life, bioavailability, dosages, LDâ‚…â‚€, or safety thresholds were available in the searches I conducted.

Hereâ€™s what the searches *did* reveal â€” which may help clarify **what you might be referring to** and what *cannot* be provided because of lack of data:

---

## ğŸ§¬ 1. There *is* an investigational peptide known as **A7R**

* The **A7R peptide** is a short heptapeptide (7-amino-acid peptide) that **binds to neuropilin-1 (NRP-1)** and vascular endothelial growth factor receptor-2 (VEGFR2), blocking VEGF165-mediated angiogenesis in cancer models, and has been studied in experimental oncology for **anti-angiogenic and tumor-targeting purposes**. ([PMC][1])

**Pharmacological actions reported in research (preclinical):**

* **Anti-angiogenic:** competes with VEGF165 for NRP-1/VEGFR2 binding, *reducing angiogenesis and tumor growth* in animal models. ([PMC][1])
* **Tumor vasculature alteration:** may â€œnormalizeâ€ chaotic tumor blood vessels in some models. ([cell.com][2])

**Key points:**

* A7Râ€™s effects are *mechanistic/targeted* (blocking growth factor signaling), not general systemic pharmacology.
* It is *not* an approved drug â€” characterization is limited to experimental models.

ğŸ›‘ **What is *not* available in the literature that you asked for:**

* **Half-life in blood or tissues**
* **Bioavailability via oral, intravenous, subcutaneous, or other routes**
* **Dosage regimens**
* **Minimum effective dose, safe range, maximum tolerated dose**
* **LDâ‚…â‚€ or toxicity thresholds**

No controlled human or animal PK/PD studies with quantitative pharmacokinetic values are published for A7R. These parameters simply donâ€™t exist in established literature for this peptide.

---

## âš ï¸ 2. Other A-7 or A7-named peptides are different

There are *other research peptides* with â€œA7â€ in their name but **not the same thing**:

### ğŸ§ª 7-amino-acid peptides (e.g., 7P)

* A 7-amino-acid sequence studied for **anti-inflammatory effects in mouse asthma models** (reduced Th2 cytokines, reduced airway hyperresponsiveness). ([PubMed][3])
* This is a different sequence and was examined only in preclinical disease models.

### ğŸ§¬ A7-1 peptide in wound healing

* A synthetic peptide tested in mice for **accelerating wound and skin graft healing**, but *no systemic pharmacokinetic or safety profile* is available. ([link.springer.com][4])

None of these are standardized therapeutic agents with regulatory approval.

---

## ğŸ§ª Why thereâ€™s *no pharmacological profile* available

Peptides like A7R are studied mainly **as experimental tools or targeting ligands** in laboratory research:

* Peptides without modifications are rapidly degraded by proteases in blood and the digestive tract, leading to very **short half-lives and poor oral bioavailability**. This is a well-known issue for peptides generally. ([sciencedirect.com][5])
* Detailed toxicology (LDâ‚…â‚€), bioavailability, and dosage profiles are typically determined **only in drug development programs** under regulatory studies â€” these have *not been published* for A7R or â€œA-7â€ complexes.

---

## ğŸ” General remarks on peptide pharmacology (relevant but *not specific* to A7R)

**Pharmacokinetic tendencies of small peptides:**

* **Half-life:** Many unmodified peptides are cleared within minutes to a few hours in blood. ([peptiderecon.com][6])
* **Bioavailability:**

  * Oral: very poor due to gastric/intestinal degradation. ([sciencedirect.com][5])
  * Parenteral (e.g., IV or subcutaneous): higher systemic exposure, but still short unless engineered. ([peptiderecon.com][7])

These general rules explain *why specific PK values for A7R arenâ€™t published* â€” its unmodified form likely would have very limited systemic bioavailability and a short half-life, but the exact values are not established.

---

## ğŸ§« Summary

| Parameter                    | **Data available?**              | Notes                                     |
| ---------------------------- | -------------------------------- | ----------------------------------------- |
| Pharmacological actions      | âœ• (for A-7 complex specifically) | Only A7R actions known in research        |
| Time-course/PK values        | âœ•                                | No published half-life, Tmax, Cmax        |
| Bioavailability (oral/IV/SC) | âœ•                                | Not determined in literature              |
| Dosage & safe range          | âœ•                                | No clinical dosing data                   |
| Minimum effective dose       | âœ•                                | Only context-dependent experimental doses |
| LDâ‚…â‚€ / toxicity              | âœ•                                | No formal toxicity studies published      |

**Conclusion:** There is **no complete pharmacological profile published** for a â€œpeptide complex A-7â€ that meets your requested depth. The closest relevant scientific subject â€” **A7R peptide** â€” is an experimental antiangiogenic peptide studied in preclinical cancer research, and *quantitative pharmacokinetics/toxicology data arenâ€™t available in the literature*. ([PMC][1])

---

If you can provide more context â€” for example, whether â€œA-7â€ refers to a *specific sequence, brand, research peptide, or therapeutic candidate* you saw in a study â€” I might be able to help locate more targeted information or clarify terminology.

[1]: https://pmc.ncbi.nlm.nih.gov/articles/PMC7032227/?utm_source=chatgpt.com "The functions and applications of A7R in anti-angiogenic ..."
[2]: https://www.cell.com/matter/fulltext/S2590-2385%2822%2900210-7?utm_source=chatgpt.com "Transforming â€œcoldâ€ tumors into â€œhotâ€ ones via ..."
[3]: https://pubmed.ncbi.nlm.nih.gov/34673034/?utm_source=chatgpt.com "7-Amino acid peptide (7P) decreased airway inflammation ..."
[4]: https://link.springer.com/article/10.1186/s12938-024-01247-7?utm_source=chatgpt.com "Wound healing induced by new synthetic peptide, A7-1, in ..."
[5]: https://www.sciencedirect.com/org/science/article/pii/S1543839222001027?utm_source=chatgpt.com "Peptides as Pharmacological Carriers to the Brain: Promises, Shortcomings and Challenges - ScienceDirect"
[6]: https://peptiderecon.com/intelligence/intel-half-life?utm_source=chatgpt.com "INTEL REPORT: Half-Life Data Compilation | Peptide Recon"
[7]: https://peptiderecon.com/intel-mechanisms?utm_source=chatgpt.com "INTEL REPORT: Comparative Mechanisms of Action in Therapeutic Peptides | Peptide Recon"
